BioNTech (BNTX) Ended A Phase 2 Colorectal Cancer Trial

BioNTech (NasdaqGS:BNTX) halted a Phase 2 trial of its individualized mRNA immunotherapy in colorectal cancer after an independent Data Safety Monitoring Board recommended termination for futility. The board cited a numerical imbalance in overall survival between treatment arms as a key factor in its decision. The discontinued study involved BioNTech's collaboration with Genentech and targeted colorectal cancer, an area described as having significant unmet medical need. This is the first...